1
Chronic Respiratory Disease Research Center ( CRDRC ), National Research Institute of Tuberculosis and Lung Disease ( NRITLD ), Shahid Beheshti University of Medical Sciences, Tehran, Iran
2
Telemedicine Research Center of Masih Daneshvari Hospital, Chronic Kidney Disease Research Center, Shahid Beheshti university of Medical Sciences, Tehran, Iran
3
Pediatric Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease ( NRITLD ), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Yassari, F., Mirenayat, M. S., Fakharian, A., Rashid-Farokhi, F. & Honarpisheh, P. (2023). Remdesivir in Patients with Advanced Renal Failure and COVID-19. TANAFFOS (Respiration), 22(3), 276–278.
MLA
Yassari, F., Mirenayat, M. S., Fakharian, A., Rashid-Farokhi, F., & Honarpisheh, P. "Remdesivir in Patients with Advanced Renal Failure and COVID-19", TANAFFOS (Respiration), 22, 3, 2023, 276–278.
HARVARD
Yassari, F., Mirenayat, M. S., Fakharian, A., Rashid-Farokhi, F., & Honarpisheh, P. (2023). 'Remdesivir in Patients with Advanced Renal Failure and COVID-19', TANAFFOS (Respiration), 22(3), pp. 276–278.
CHICAGO
Yassari, F., Mirenayat, M. S., Fakharian, A., Rashid-Farokhi, F. & Honarpisheh, P., "Remdesivir in Patients with Advanced Renal Failure and COVID-19." TANAFFOS (Respiration), 22 3 (2023): 276–278,
VANCOUVER
Yassari F., Mirenayat M. S., Fakharian A., Rashid-Farokhi F., Honarpisheh P. Remdesivir in Patients with Advanced Renal Failure and COVID-19. TANAFFOS (Respiration). 2023;22(3):276–278.
